Abstract
Ageing is the major risk factor for Alzheimer’s disease (AD), a condition involving brain hypoxia. The majority of early-onset familial AD (EOfAD) cases involve dominant mutations in the gene PSEN1. PSEN1 null mutations do not cause EOfAD. We exploited putative hypomorphic and EOfAD-like mutations in the zebrafish psen1 gene to explore the effects of age and genotype on brain responses to acute hypoxia. Both mutations accelerate age-dependent changes in hypoxia-sensitive gene expression supporting that ageing is necessary, but insufficient, for AD occurrence. Curiously, the responses to acute hypoxia become inverted in extremely aged fish. This is associated with an apparent inability to upregulate glycolysis. Wild-type PSEN1 allele expression is reduced in post-mortem brains of human EOfAD mutation carriers (and extremely aged fish), possibly contributing to EOfAD pathogenesis. We also observed that age-dependent loss of HIF1 stabilization under hypoxia is a phenomenon conserved across vertebrate classes.
Introduction
Alzheimer’s disease (AD) is the most prevalent form of dementia. Decreased levels of soluble amyloid-beta (Aβ) peptides in cerebrospinal fluid (1) (presumably due to decreased clearance from the brain) are regarded as one of the earliest markers of both early-onset familial AD (EOfAD) and late-onset sporadic AD (LOsAD), preceding disease onset by 20–30 years (2,3), while vascular changes may occur even earlier (4). When AD clinical symptoms eventually become overt, neurodegeneration may be too advanced for effective therapeutic intervention. This may explain the failure of drugs designed to inhibit supposed Aβ-related pathological processes to halt cognitive decline (5,6).
There are numerous observations implicating brain hypoxia in AD. For example, cardiovascular risk factors strongly correlate with LOsAD (7,8). Other significant LOsAD risk factors include vascular brain injury and traumatic brain injury (9), while recent studies suggest that aerobic exercise can reduce AD risk (10,11). Reduced blood flow has been observed in AD brains (12,13) most likely causing impaired oxygenation. Hypoxia can induce the expression of EOfAD genes/proteins (14–17) to drive Aβ production and a serum biomarker associated with hypoxia can predict which people with mild cognitive impairment (MCI) will progress to AD and which will not (18). An important controller of cellular responses to hypoxia is the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF1), which is comprised of HIF1α and HIF1β monomers. HIF1α protein is decreased in LOsAD brains compared to age-matched controls (19), although the reason for this is unknown.
The molecular events underlying LOsAD are complex and have eluded detailed understanding. However, EOfAD is caused by inherited, dominant mutations in the genes, presenilin 1 (PSEN1), presenilin 2 (PSEN2), amyloid beta A4 precursor protein (APP) and sortilin related receptor (SORL1) (20,21) and so is amenable to genetic analysis in animal models. Only 5.5% of AD is defined as EOfAD (22). Nevertheless, the similarity in clinical disease progression and brain pathology of EOfAD and LOsAD (23) supports the assumption that genetic analysis of EOfAD will contribute to understanding of both forms of the disease.
PSEN1 and PSEN2 are alternative catalytic components of the γ-secretase complexes that cleave APP to form Aβ. On a population basis, ~60% of all EOfAD mutations occur in PSEN1 (24) and are viewed mostly as altering the cleavage of APP to yield changes in the relative abundance of different Aβ size forms. Nevertheless, the exact relationship between EOfAD mutations in the presenilin genes and APP is still a matter of debate (25,26).
Structural and functional brain imaging (Magnetic resonance imaging (MRI) and/or positron emission tomography (PET)) from individuals with EOfAD mutations has revealed changes as early as 9 years of age (27,28). Elevations in Aβ deposition and reduced glucose metabolism have also been observed in EOfAD brains years before symptom onset (29). Surprisingly, there has been little detailed molecular investigation of the young adult brains of any animal model closely mimicking the human EOf genetic state—i.e. heterozygous for an EOfAD-related mutation in a single, endogenous gene. Therefore, to model and explore early changes in the brain driving AD pathogenesis, we have edited the zebrafish genome to introduce EOfAD-related mutations into the endogenous, PSEN1-equivalent gene of zebrafish, psen1. We recently published transcriptomic analyses of two such mutations, psen1K97fs and psen1Q96_K97del (30,31).
An analysis of the psen1K97fs mutation in young and aged brains revealed that this mutation accelerates elements of brain ageing (31). However, we now know that this frameshift mutation differs from its human archetype (PSEN2K115fs) in failing to restore the open reading frame (ORF) of various frameshifting alternative transcripts (31,32). (All EOfAD alleles of PSEN1 and PSEN2 follow the ‘reading frame preservation rule’ by producing transcripts encoding altered protein sequences without premature termination codons) (25,33). psen1K97fs most likely represents a protein-truncating, hypomorphic allele similar to the human PSEN1P242fs allele that causes the skin disease familial hidradenitis suppurativa without EOfAD (34). In contrast, the more EOfAD-like psen1Q96_K97del mutation precisely deletes two codons thus following the reading frame preservation rule. It resembles numerous human EOfAD mutations by altering the structure of the first lumenal loop of PSEN1 (a multipass transmembrane protein of the endoplasmic reticulum and other organelles) (35).
A gene ontology analysis of young adult zebrafish brain transcriptomes revealed that, in contrast to psen1K97fs, the more EOfAD-like psen1Q96_K97del mutation is predicted to have very significant effects on mitochondrial function, especially synthesis of ATP, and on ATP-dependent functions such as the acidification of lysosomes that are critical for autophagy (36). The importance of oxygen for production of ATP by mitochondria, the apparent role of hypoxia in AD and the little-studied interaction between PSEN1 protein and HIF1α (37,38) led us to question whether our two zebrafish psen1 mutants would differ in their responses to hypoxia with age.
We found that zebrafish brain gene expression responses to hypoxia increase greatly with age but that extremely aged brains ‘invert’ to show opposite responses. The hypomorphic and the EOfAD-like mutations of psen1 both accelerate the onset of this inversion. Expression of the psen1 gene itself under normoxia also increases with age until this reverses in extremely aged brains. Loss of PSEN1 expression is also observed in human EOfAD brain tissue compared to age-matched controls supporting that these brains are subject to accelerated ageing. The more EOfAD-like mutation of psen1 causes an abnormal, and possibly pathogenic, stabilization of a zebrafish HIF1α paralogue that becomes evident in aged brains.
Results
The ability to generate large families of siblings (over 100 individuals) and hold them in the same environment (the same tank) reduces genetic and environmental noise in omics analyses while allowing sampling of large numbers of individuals for statistical power. We have previously exploited this in our studies of EOfAD-related mutation model brain transcriptomes (31,32). In these studies, we typically generate families in which half the siblings are heterozygous mutants (modelling the human carriers of dominant EOfAD mutations) and half the siblings are non-mutant (i.e. wild-type). Serendipitously, not all the individuals of these large families are required for the omics analyses, so that follow-up experiments can be performed on individuals of various ages from families generated at various times. To investigate the interaction between age and our mutations on responses to hypoxia, we sampled families extant in our zebrafish facility. As the individuals involved were those surplus to the needs of planned omics studies, it was not always possible to analyse equal numbers of females and males. However, a principal component analysis of transcriptome data has not revealed sex to be a major determinant of zebrafish brain molecular state (see Supplementary Material, Fig. S1).
We exposed zebrafish to acute hypoxia by placement in oxygen-depleted water (0.6 ± 0.2 mg/L O2) for 3 h after which they were rapidly euthanized and their brains removed for analysis.
Accelerated loss of hypoxia responses in ageing mutant zebrafish brains
During hypoxia, cells promote survival by adjusting their energy metabolism. In part, this is controlled at the transcriptional level by changes in the expression of hypoxia response genes (HRGs) (39). These genes include PDK1 encoding pyruvate dehydrogenase kinase 1 that phosphorylates pyruvate dehydrogenase to inhibit conversion of pyruvate to acetyl-CoA (40). In this way, pyruvate is directed away from the tricarboxylic acid cycle and oxidative phosphorylation and into ATP production via anaerobic glycolysis. Thus, PDK1 acts as a form of ‘rheostat’ to set the relative rates of anaerobic glycolysis and oxidative phosphorylation. To determine the effects of age and our psen1 alleles on genetic responses to hypoxia, we used digital quantitative PCR (dqPCR) to assess transcript levels from four HRGs: cd44a, igfbp3, mmp2 (41) and pdk1 (42) in the brains of zebrafish exposed to normoxia or acute hypoxia.
Unexpectedly, the responses of heterozygous zebrafish carrying either of our two psen1 mutant alleles were essentially identical and very different to those of wild-type siblings (Fig. 1A and B; Tables 1 and 2; Supplementary Material, Data S1). Young, 6-month-old mutants show increased basal levels of HRG expression under normoxia suggestive of pre-existing hypoxic stress, although other explanations are possible such as alteration of iron homeostasis or alteration of basal γ-secretase levels (see the Discussion). Nevertheless, both wild-type and mutant young adult zebrafish were able to increase HRG expression under acute hypoxia. Aged, 24-month-old wild-type zebrafish showed increased basal HRG expression under normoxia, resembling HRG expression in the young mutant animals (Fig. 1A and B; Tables 1 and 2; Supplementary Material, Data S1). This is consistent with our previous observation that the psen1K97fs mutation accelerates brain ageing (31). Despite their increased level of HRG expression under normoxia, the 24-month-old wild-type brains could still respond further to hypoxia with an approximately 2-fold increase in HRG expression. Interestingly, their levels of HRG expression were then very similar to those of normoxic 24-month-old psen1K97fs and psen1Q96_K97del mutant zebrafish brains (Fig. 1A and B; Tables 1 and 2; Supplementary Material, Data S1), again supporting that these mutant brains are under hypoxic stress.
Figure 1 .

HRG expression in zebrafish brains under normoxia and hypoxia. Each data point on the graph indicates the relative transcript level for cd44 (●), igfbp3 (▲), mmp2 (▼) and pdk1 (♦) in 50 ng of cDNA generated from a single zebrafish brain RNA sample, assuming reverse transcription is complete (filled symbols, females; outlined symbols, males). Copy numbers for each transcript in each sample were scaled to the normalized means of the transcript copy numbers in the wild-type 6 months normoxia samples. The age and genotype of each sample are indicated at the top of the graph. Grey backgrounds indicate the hypoxia-treated samples. Wild-type (+/+), psen1K97fs/+ (K97fs/+) heterozygous mutant and psen1Q96_K97del/+ (Q96_K97del/+) heterozygous mutant. P-value of < 0.05 for differentially expressed (DE) genes determined by t-test: two-sample assuming unequal variances. Solid lines flanking bidirectional arrows indicate comparisons in t-tests. The genes significantly DE are indicated below the bidirectional arrow. HRGs are HIF-1-responsive genes. The colour of the solid lines indicates the direction of differential expression; dark grey indicates increased expression and white (with dark grey outline) indicates decreased expression. Dark grey and white (with dark grey outline) arrows indicate the direction of pdk1 expression change under hypoxia (arrow ends connect pdk expression means). The raw dqPCR data, P-values and fold changes for all comparisons made are given in Tables 1 and 2 and Supplementary Material, Data S1. (A) HRG expression in K97fs/+ and +/+ siblings (6 months and 24 months). (B) HRG expression in Q96_K97del/+ and +/+ siblings (6 months, 24 months and 42 months).
Table 1.
P-values calculated for comparisons of HRG expression in 6-month-old and 24-month-old zebrafish brains under normoxia and hypoxia (K97fs/+ versus +/+ siblings)
| 6 months | Normoxia, +/+ versus K97Gfs/+ | +/+, Normoxia versus hypoxia | K97fs/+, Normoxia versus hypoxia | K97fs/+ normoxia versus +/+ hypoxia | |
|---|---|---|---|---|---|
| P = | P = | P = | P = | ||
| cd44a | 0.00783228 | 0.006314391 | 0.001663059 | 0.28801924 | |
| igfbp3 | 0.165463511 | 0.01694569 | 0.050922675 | 0.236891265 | |
| mmp2 | 0.161245754 | 0.001817468 | 0.010295962 | 0.00032791 | |
| pdk1 | 0.012157721 | 0.004652282 | 0.013814721 | 0.108391519 | |
| 24 months | Normoxia, +/+ versus K97Gfs/+ | Hypoxia, +/+ versus K97Gfs/+ | +/+, Normoxia versus hypoxia | K97fs/+, Normoxia versus hypoxia | K97fs/+ normoxia versus +/+ hypoxia |
| P = | P = | P = | P = | P = | |
| cd44a | 0.00905243 | 0.000164359 | 0.000482095 | 0.015923746 | 0.606823905 |
| igfbp3 | 0.00758629 | 0.000171843 | 0.000578267 | 0.010219623 | 0.660525701 |
| mmp2 | 0.01134734 | 0.022886107 | 0.013072996 | 0.001327811 | 0.078629161 |
| pdk1 | 0.011036627 | 0.040541648 | 0.033578682 | 0.013009494 | 0.997382256 |
| 6 months versus 24 months | Normoxia +/+, 6 months versus 24 months | Normoxia, K97fs/+ 6 months versus +/+ 24 months | |||
| P = | P = | ||||
| cd44a | 0.005215672 | 0.221551983 | |||
| igfbp3 | 0.169616519 | 0.569035161 | |||
| mmp2 | 0.091145915 | 0.226718693 | |||
| pdk1 | 0.00559651 | 0.135261456 |
Table 2.
P-values calculated for comparisons of HRG expression in 6-month-old and 24-month-old zebrafish brains under normoxia and hypoxia (Q96_K97del/+ and +/+ siblings)
| 6 months | Normoxia, +/+ versus Q96_K97del/+ | +/+, Normoxia versus hypoxia | Q96_K97del/+, normoxia versus hypoxia | Q96_K97del/+ normoxia versus +/+ hypoxia | |
|---|---|---|---|---|---|
| P = | P = | P = | P = | ||
| cd44a | 0.001345558 | 1.86483E-05 | 0.000179018 | 0.072598115 | |
| igfbp3 | 0.003367147 | 2.27148E-09 | 0.00397462 | 0.02465246 | |
| mmp2 | 0.005874266 | 1.3017E-05 | 4.79431E-05 | 0.000111507 | |
| pdk1 | 0.003270849 | 8.95189E-07 | 0.007483553 | 0.130392718 | |
| 24 months | Normoxia, +/+ versus Q96_K97del/+ | Hypoxia, +/+ versus K97Gfs/+ | +/+, Normoxia versus hypoxia | Q96_K97del/+, normoxia versus hypoxia | Q96_K97del/+ normoxia versus +/+ hypoxia |
| P = | P = | P = | P = | P = | |
| cd44a | 0.00083616 | 0.000107684 | 2.94348E-10 | 0.094123248 | 0.394019836 |
| igfbp3 | 1.53017E-05 | 0.03464859 | 2.94718E-08 | 0.066237546 | 0.427249042 |
| mmp2 | 8.07458E-07 | 0.000183921 | 5.86897E-05 | 1.97472E-05 | 0.386488096 |
| pdk1 | 2.03058E-05 | 0.010855063 | 3.0078E-06 | 0.004855014 | 0.408870671 |
| 42 months | Normoxia, +/+ versus Q96_K97del/+ | Hypoxia, +/+ versus Q96_K97del/+ | +/+, Normoxia versus hypoxia | Q96_K97del/+, normoxia versus hypoxia | Q96_K97del/+ normoxia versus +/+ hypoxia |
| P = | P = | P = | P = | P = | |
| cd44a | 0.328796317 | 0.134697144 | 0.197046713 | 0.209525094 | 0.747621218 |
| igfbp3 | 0.000483699 | 0.066773494 | 0.411560109 | 0.008598631 | 0.000178563 |
| mmp2 | 0.004127582 | 0.225910368 | 0.924628722 | 0.003053477 | 0.00414743 |
| pdk1 | 0.322016804 | 0.994950955 | 0.008062354 | 0.002345495 | 0.003389143 |
| 6 months versus 24 months | Normoxia +/+, 6 months versus 24 months | Normoxia, Q96_K97del/+ 6 months versus +/+ 24 months | |||
| P = | P = | ||||
| cd44a | 3.82053E-06 | 0.014740525 | |||
| igfbp3 | 0.701769718 | 0.002526586 | |||
| mmp2 | 0.00343619 | 0.493485411 | |||
| pdk1 | 0.189449494 | 0.007242434 |
The greatest surprise came when aged, 24-month-old brains heterozygous for either psen1 mutation were subjected to acute hypoxia. Rather than further upregulating HRG expression, they either failed to do this or they even downregulated HRG expression (Fig. 1A and B, P-values in Tables 1 and 2; Supplementary Material, Data S1). This inversion of the expected hypoxia response was particularly noticeable for expression of pdk1, suggesting an inability to upregulate anaerobic glycolysis in aged EOfAD-related mutant zebrafish under hypoxia. Assays of lactate content (a marker of anaerobic glycolysis) in brains both from young (7 months) and aged (31 months) psen1Q96_K97del fish under acute hypoxia were consistent with this predicted failure to upregulate anaerobic glycolysis (Fig. 2). However, in contrast to pdk1 expression, there was no apparent upregulation of anaerobic glycolysis in young wild-type brains under acute hypoxia (an observation also reported for young mouse brains under chronic hypoxia) (43).
Figure 2 .

Lactate in 7-month-old and 31-month-old zebrafish brains under normoxia and hypoxia. Each data point on the graph indicates lactate content in a single whole zebrafish brain. All zebrafish were female. The age and genotype of each sample are indicated at the top of the graph. Grey backgrounds indicate the hypoxia-treated samples. Wild-type (+/+) and psen1Q96_K97del/+ (Q96_K97del/+) heterozygous mutant. P-values are calculated using t-test: two-sample assuming unequal variances. Raw lactate assay data is given in Supplementary Material, Data S2. Lactate concentration is expressed as nmol per mg of whole brain from Q96_K97del/+ zebrafish and their +/+ siblings.
If fAD-like mutations accelerate brain ageing, do wild-type brains eventually show the same failure of HRG expression as they age? To test this, we examined psen1Q96_K97del mutant and wild-type sibling brains under normoxia or acute hypoxia at 42 months of age (Fig. 1B). (Laboratory-reared zebrafish are reported to have a mean life span of ~ 42 months (44), and we were fortunate enough to have psen1Q96_K97del mutants and wild-type siblings surviving to this extreme age, however, there were no psen1K97fs mutants and their wild-type siblings available at this age). The levels of HRG expression in brains of both psen1Q96_K97del mutants and wild-type siblings are essentially the same under normoxia, and both show downregulation of HRG expression under acute hypoxia (Fig. 1B). This clearly supports that fAD-like mutations accelerate brain ageing and that an inability to upregulate HRG expression under acute hypoxia may be an inevitable consequence of ageing.
Does decreased function of wild-type psen1 accelerate brain ageing?
Since age is the greatest risk factor for AD, the idea that EOfAD mutations of psen1 might accelerate brain ageing seemed a parsimonious explanation for their pathogenicity. Therefore, we were surprised that both the less and the more EOfAD-like mutations of psen1 appear to accelerate ageing in terms of HRG responses. This suggests the possibility that the levels of wild-type psen1 allele expression are critical to the acceleration of brain ageing rather than the presence of the mutations themselves. Unfortunately, despite repeated attempts, so far we have been unable to generate an antibody with which to assay zebrafish Psen1 protein levels. However, dqPCR allows us to assay and compare the relative levels of wild-type and mutant psen1 transcripts in zebrafish brains.
Premature termination codons commonly cause decreased mRNA transcript stability though the process of nonsense-mediated decay (NMD) (45). The psen1K97fs allele results in a premature termination codon (after 11 frameshifted amino acid codons) in exon 4 and its expression level is significantly decreased compared to transcripts from the wild-type psen1 allele (Fig. 3A). This supports that the effects of psen1K97fs are due to loss of function. Indeed the expression level of the wild-type allele in the psen1K97fs heterozygous fish brains is approximately half that of wild-type sibling fish brains at both 6 months and 24 months of age (Fig. 3A). There is no evidence of upregulation of the wild-type allele in the psen1K97fs heterozygous fish such as might be caused by the phenomenon of ‘genetic compensation’ that can be driven by NMD (46). Note however that, if the psen1K97fs allele produces a truncated protein product, it is not expected to be completely without function (see Discussion).
Figure 3 .

Allele-specific psen1 transcript expression in 6-month-old and 24-month-old zebrafish brains. Each data point on the graph indicates psen1 transcript copy number in 50 ng of cDNA generated from a single zebrafish brain RNA sample, assuming reverse transcription is complete. The age and genotype of each sample is indicated at the top of the graph. Wild-type (+/+), psen1K97fs/+ (K97fs/+) heterozygous mutant and psen1Q96_K97del/+ (Q96_K97del/+) heterozygous mutant. P-values are calculated using t-test: two-sample assuming unequal variances. Raw dqPCR data and P-values are given in Supplementary Material, Data S4. (A) Allele-specific expression of either wild type psen1 (+, black circles) or mutant psen1 (K97fs, grey squares) or psen1+ and psen1K97fs combined (light grey hexagons) (all females). (B) Allele-specific expression of wild type psen1 (+, black circles) and mutant psen1 (Q96_K97del, grey squares) or psen1+ and psen1Q96_K97del combined (light grey hexagons) (filled symbols: females, outlined symbols: males). The 6-month-old and 24-month-old +/+ data are also included in Figure 5. They are included/repeated in this figure for comparison to data from their heterozygous mutant siblings.
The mutant transcripts in the EOfAD-like psen1Q96_K97del heterozygous fish brains possibly show somewhat decreased expression compared to wild-type transcripts although this was not statistically significant (at the P < 0.05 level, Fig. 3B). However, unlike in the psen1K97fs heterozygous fish, the level of wild-type allele expression in heterozygous psen1Q96_K97del fish brains is similar to that seen in wild-type siblings of the same age. Something must drive this increased level of wild-type allele expression. If the accelerated ageing of these fish is due to decreased wild-type allele function, then this could be due to interference from the mutant protein product of the psen1Q96_K97del allele (see Discussion).
Evidence for accelerated brain ageing in human EOfAD
Mutations of human PSEN1 (or PSEN2) that prevent any ORFs from utilizing the original termination codon have never been seen to cause EOfAD (in line with the ‘reading frame preservation rule’) (25). A notable difference between the zebrafish psen1K97fs and psen1Q96_K97del alleles is that only the latter obeys the reading frame preservation rule and only this EOfAD-like mutation upregulates wild-type psen1 allele expression to equal or exceed that in wild-type fish. Does a similar upregulation of PSEN1 gene expression occur in human EOfAD? To test this, we used dqPCR to examine wild-type and mutant PSEN1 allele expression in three post-mortem EOfAD brains (medial temporal cortex region without significant neuropathology) and in healthy, age-matched controls (Fig. 4). Consistent with our psen1Q96_K97del mutant data, transcripts of the mutant human mutant PSEN1 allele were always detectable and at approximately half the level of the transcripts from the wild-type allele. However, expression of the wild-type allele was lower than in the age-matched controls (Fig. 4). We reasoned that, since mutation of psen1 in zebrafish appears to accelerate brain ageing and since the human EOfAD brains were from people who had died from this disease, their decreased human PSEN1 expression might represent a phenomenon more similar to gene expression in extremely aged fish brains. Therefore, we compared the relative psen1 gene expression levels between the young (6 months), aged (24 months) and extreme aged (51 months) wild-type female fish brains. (Mutant fish brain cDNAs were not available for this experiment.) We observed the expected increase in psen1 expression from 6 to 24 months but then a significant decrease in expression by 51 months (Fig. 5). This supports that human brains with overt EOfAD may display the equivalent of an ‘extremely aged’ molecular state giving them a lower level of PSEN1 expression than chronologically age-matched healthy brains that are, in reality, less aged biologically.
Figure 4 .

PSEN1 transcript expression in the middle temporal gyrus region of brains of PSEN1 mutation carriers and age-matched controls. Age-matched control (control, with corresponding mutation carrier sample in parentheses), PSEN1L271V/+ heterozygous mutation carrier (L271V/+), PSEN1L219P/+ heterozygous mutation carrier (L219P/+) and PSEN1G206V/+ heterozygous mutation carrier (G206V/+). Raw dqPCR data is given in Supplementary Material, Data S3. (A) Expression of wild-type (PSEN1+) and L271V mutant (PSEN1L271V) alleles in control (51 years old) and L271V/+ (51 years old) cDNA samples. (B) Expression of either wild-type (PSEN1+) and L219P mutant (PSEN1L219P) alleles in control (60 years old) and L219P/+ (61 years old) cDNA samples. (C) Expression of either wild-type (PSEN1+) and G206V (PSEN1G206V) alleles in control (29 years old) and G206V/+ (32 years old) cDNA samples. The normalized PSEN1 gene expression data (two different reference genes, CYC1 and RPL13) is given in Supplementary Material, Data S3.
Figure 5 .

Wild-type psen1 allele expression in 6-month-old, 24-month-old and 51-month-old wild-type zebrafish brains. Each data point on the graph indicates psen1 transcript copy number in 50 ng of cDNA generated from a single zebrafish brain RNA sample, assuming reverse transcription is complete. All samples are wild-type females. The age of each sample is indicated at the bottom of the graph. P-values are calculated using t-test: two-sample assuming unequal variances. Raw dqPCR data are given in Supplementary Material, Data S3. Note that the data for the 6-month-old and 24-month-old samples are also presented in Figure 3. It is duplicated here for easy comparison to the 51-month-old samples.
Interestingly, the age-dependent changes in brain transcript expression of a zebrafish paralogue of HIF1α (hif1ab) mirror closely those of psen1 expression but are very different from its protein expression (see below and Fig. 6).
Figure 6 .

Hif1ab allele expression in 6-month-old, 24-month-old and 51-month-old wild-type zebrafish brains. Each data point on the graph indicates psen1 transcript copy number in 25 ng of cDNA generated from a single zebrafish brain RNA sample, assuming reverse transcription is complete. All samples are wild-type female. The age of each sample is indicated at the bottom of the graph. P-values are calculated using t-test: two-sample assuming unequal variances. Raw dqPCR data are given in Supplementary Material, Data S4.
Loss of HIF1 in aged brains is conserved across vertebrate species
HIF1α is one component of the heterodimeric transcription factor HIF1 that plays an important role in cellular responses to hypoxia. Hypoxia increases the stability of HIF1α protein, thus increasing HIF1 levels and upregulating a large number of HRGs. In a study of brain ageing and responses to hypobaric hypoxia in rats, Ndubuizu et al. (47,48) observed an inability to stabilize Hif1α under hypoxia after 18 months of age. To test whether this phenomenon might explain the inability of extremely aged zebrafish brains to upregulate HRGs in response to acute hypoxia, we used an antibody against the paralogous zebrafish protein Hif1ab. We observed that wild-type zebrafish already fail to stabilize Hif1ab from 24 months of age (Fig. 7A and B), at a time when their basal HRG expression is raised compared to younger fish, and during which they can still greatly increase HRG expression under hypoxia (as shown in Fig. 1). This shows that a failure to stabilize Hif1a in aged vertebrate brains is a characteristic conserved over an evolutionary period of greater than 430 million years (i.e. since the divergence of the teleost and tetrapod lineages) (49) but this does not explain the ‘inversion’ of HRG expression responses to hypoxia in aged zebrafish brains.
Figure 7 .

Hif1ab protein levels in 6-month-old and 24-month-old zebrafish brains under normoxia and hypoxia. Each data point on the graph indicates the Hif1ab protein level in protein extracted from a single zebrafish brain (filled circles, females; outlined circles, males). The age and genotype of each sample are indicated at the top of the graph. Grey backgrounds indicate the hypoxia-treated samples. Wild-type (+/+), psen1K97fs/+ (K97fs/+) heterozygous mutant and psen1Q96_K97del/+ (Q96_K97del/+) heterozygous mutant. P-values are calculated using t-test: two-sample assuming unequal variances on Ln transformed data. Raw densitometry data and P-values are given in Supplementary Material, Data S5 and western blot images are shown in Supplementary Material, Figure S2. (A) Hif1ab protein level in K97fs/+ and +/+ siblings. (B) Hif1ab protein level in Q96_K97del/+ and +/+ siblings.
The EOfAD-like mutation of psen1 drives age-inappropriate stabilization of a HIF1 paralogue under acute hypoxia
Only one previous study, De Gasperi et al. (37), has noted that PSEN1 protein directly physically interacts with HIF1α. Using immortalized mouse embryonic fibroblasts these authors noted that Psen1 is required for stabilization of Hif1α under chemical mimicry of hypoxia using CoCl2 or when treated with insulin. When mouse Psen1 expression was replaced in these cells by human EOfAD mutant PSEN1M146V, stabilization of Hif1α under chemical mimicry of hypoxia was normal but Hif1α stabilization due to insulin treatment was deficient. Our analysis of Hif1ab stabilization under acute hypoxia in aged, 24 month, zebrafish revealed a surprising difference between the heterozygous putative null mutant brains and EOfAD-like mutant brains. The EOfAD-like psen1Q96_K97del brains stabilized Hif1ab under acute hypoxia, at an age when neither the wild-type or psen1K97fs brains did this (Fig. 7). The consequences of this age-inappropriate stabilization of Hif1ab are currently unknown but this observation emphasizes the importance of observing EOfAD-like mutation activities in aged, non-transgenic animal models.
Discussion
The production of energy supports all other cellular functions and is, therefore, fundamental to cellular, tissue, organ and organismal health. As the human brain ages, vascular function gradually declines (12,13) making it more difficult to deliver oxygen and energy substrates to support the brain’s energy needs. As a consequence, transcription of HIF1α increases in the brain with age (50). Increased HIF1, acting to increase expression of PDK1, would be expected to raise the rate of anaerobic glycolysis to maintain production of ATP (that is necessary, among other things, for maintaining the solubility of proteins to prevent the protein aggregation characteristic of neurodegenerative conditions) (51). However, a primary diagnostic marker of AD brains is that they are hypometabolic with both reduced oxygen and glucose consumption (as revealed by brain imaging studies) (12,19). Also, Liu et al. (19) found evidence for reduced levels of HIF1α protein in post-mortem sporadic AD brains compared to normal, aged-matched controls. Recently, machine learning was employed to analyse structural MRI data from healthy controls and patients with dementia and other neurological conditions (52). This revealed distinct patterns of accelerated brain ageing in the dementia patients. These observations, together with our previous zebrafish psen1 mutation data showing acceleration of ageing at the level of gene expression (31) and the hypoxia response data we have presented here, are consistent with a view of AD as both a consequence of ageing and as a pathological, hypometabolic brain state.
The clarity of the responses we have observed in whole zebrafish brains is due to our ability to place these entire, tiny ~ 7 mg brains under acute hypoxia. The human brain is ~ 250 000-fold larger in mass than a zebrafish brain, and the hypoxia it experiences as a result of failing vascular function would be expected to be regional (i.e. depending on the energy demand and vascularization of different brain regions) and would spread progressively as vascular function decreases (53,54). Notably, Raz et al. (55) recently observed that hypoxic hypoperfusion in rat brain drives hyperphosphorylation of tau while Mesulam (56) noted over two decades ago that the spread of neurofibrillary tangles of hyperphosphorylated tau in human brains tracks closely with the cognitive changes of AD progression (in contrast to Aβ plaque pathology). This is further evidence that hypoxia plays an important role in AD pathogenesis.
Our data from this study are also consistent with the ‘stress threshold change-of-state’ model of AD progression we presented previously (26). That model postulates aged brains ‘inverting’ (in terms of numerous molecular characteristics) into a pathological state as they reach a homeostatic threshold such as a limit in their ability to cope with the increasing oxidative stress caused by age-related hypoxia. A number of ‘inversion’ phenomena during AD pathogenesis have previously been noted by others. For example, in a transcriptome-based comparison of various brain regions in normal aged control, MCI and AD post-mortem individuals, Berchtold et al. (57) saw upregulation in MCI of genes involved in many cellular processes including mitochondrial energy generation. Many of these genes were subsequently downregulated in AD relative to controls. Similar observations have been made for the onset of dementia in Down syndrome individuals (58). Also, Arnemann et al. (59) also saw widespread elevation of metabolic brain network correlations during healthy ageing but reduction of such correlations in AD.
Digital, dqPCR facilitates comparison of the levels of different transcripts by allowing comparison of PCRs based on different primer pairs. Using dqPCR we could observe significantly decreased levels of psen1K97fs transcripts compared to wild-type transcripts, presumably due to the mutant transcripts including a premature termination codon and so being subject to NMD. This supports a mainly hypomorphic phenotype for this allele. Any truncated protein product of psen1K97fs in heterozygous brains would lack its own γ-secretase catalytic activity. However, it would likely resemble the truncated PSEN2 isoform PS2V (60,61) and so might enhance the γ-secretase activity provided by the wild-type allele, as well as inhibiting the cellular unfolded protein response (60,62). In contrast, transcripts of the psen1Q96_K97del allele were not significantly less stable than wild-type transcripts in heterozygous brains, and their presence stimulated increased expression of the single wild-type allele. We speculate that this might be due to the mutant protein product of psen1Q96_K97del interfering with the function of the wild-type Psen1 protein, either through interference with the formation of Psen1 holoprotein multimers (25), or through dominant inhibition of γ-secretase activity (63). If either of these actions caused increased oxidative stress (e.g. by interfering with mitochondrial function) (35,64), this might upregulate the expression of psen1 (14). Notably, in wild-type fish, we observed an increase in psen1 and hif1ab transcript levels with age that subsequently decreased as the fish became extremely aged, demonstrating once again the ‘inversion’ of gene expression with extreme age.
In post-mortem human carriers of three different PSEN1 EOfAD mutations, we observed severely decreased PSEN1 transcript expression in middle temporal gyrus tissue relative to healthy controls. If loss of PSEN1 expression is also widespread in LOsAD brains, then this phenomenon may be important in AD pathogenesis. However, the published expression data for PSEN1 in human LOs brain tissue show varying results depending on the brain region studied, the method of measurement, and which particular transcript variant was measured. For example, in LOsAD brains, a decrease in expression of PSEN1 mRNA has been observed in the hippocampus (along with PSEN2) (65) and in the frontotemporal region (66) while an increase in expression of PSEN1 mRNA has been measured in the temporal lobes (67,68) and superior frontal gyrus (68). Other studies reported no significant difference in PSEN1 expression in LOsAD in the frontal cortex (69,70), the entorhinal cortex, the auditory cortex (although decreased PSEN2 was observed) or the hippocampus (71). It is difficult to form any firm conclusions on PSEN1 mRNA expression in LOsAD from these inconsistent findings. This should encourage more detailed analysis of PSEN1 expression in both EOfAD and LOsAD brains in the future, particularly to compare the consistency of changes in mRNA level with changes in protein abundance.
While our observations are consistent with mutations in PSEN genes causing accelerated ageing, there are numerous studies that question the idea of AD being an inevitable consequence of age (72–74). Even if the failure to upregulate glycolysis under hypoxia we observed in extremely aged zebrafish is related to the brain hypometabolism of AD, this does not show that AD is an inevitable consequence of ageing. Rather, our results only support that age is a major risk factor for AD and may even be a necessary precondition for the disease.
Our study has uncovered a number of phenomena that we currently cannot explain. Why is it that, under acute hypoxia, 24-month-old zebrafish brains cannot stabilize Hif1ab but are still able to upregulate HRGs? Are there HIF1-independent systems activating HRGs such as PGC1α (a key regulator of cellular energy metabolism).(48)? Why does heterozygosity for only the EOfAD-like mutation in psen1 (that does not truncate the open reading frame) allow unexpected stabilization of Hif1ab under hypoxia at an age when upregulation of HRGs fails? Indeed, why do transcript levels of HRGs decrease under hypoxia in these fish rather than increasing or, at least, not changing? Clearly, neither age nor the presence of mutations in psen1 alone is sufficient to explain these phenomena and an interaction between the two factors is involved. One possible explanation would be that the psen1 mutant brains are undergoing neurodegeneration. Indeed, our recent brain transcriptomic analyses on these two psen1 mutations revealed alterations to inflammatory and immune pathways in aged psen1 mutant brains (31,75). As inflammatory pathways are associated with neurodegeneration, these brains may be in the early stages of neurodegeneration or on a path towards it. However, a previous histological analysis of 24-month-old psen1K97fs heterozygous mutant brains did not find obvious pathology (31) and neither psen1 mutation showed evidence of altered cell death pathways in transcriptomic analyses (31,75). Zebrafish have a high regenerative capacity following tissue damage that includes repair of nervous tissue (76) and previous attempts to model neurodegenerative diseases in adult zebrafish have failed to show cellular phenotypes (77). Therefore, we believe it unlikely that the effects we have seen in this study can be explained by the presence of significant neurodegeneration due to psen1 mutation.
HIF1α has been shown to interact physically with PSEN1 protein (37,38) and a physical interaction of HIF1α with the γ-secretase complex (presumably via PSEN1) can increase γ-secretase activity (38). In turn, increased γ-secretase activity can increase HIF1α stability (and so HIF1 activity) via a p75NTR-dependent feed-forward mechanism (78). For this reason, and the known stabilization of HIF1α by ferrous iron deficiency (79,80) (that can be caused by failure of lysosomal acidification) (81), we are unable to assert with certainty that the increased basal HRG expression seen in our heterozygous psen1 mutant brains is due to hypoxia. Further work will be required to dissect the influences of psen1 mutations on HRG expression in young brains and to understand the inappropriate stabilization of Hif1ab in aged, EOfAD-like psen1 mutant brains.
The experimental results described in this paper emphasize the intimate interaction between age, PSEN1 (the majority locus for EOfAD mutations) and the HIF1 master controller of cellular hypoxia responses and energy metabolism. Maintaining vascular health and youthful brain hypoxia responses is likely a key to avoiding or delaying the onset of AD. For human EOfAD mutation carriers, a recent systematic review has revealed an association between physical exercise and better cognitive outcomes at expected symptom onset ages (82). This is consistent with physical exercise being one of the few known protective treatments against LOsAD (83–86).
Materials and Methods
Zebrafish husbandry and animal ethics
All experiments, except for digital PCRs for psen1 transcript expression in 6-month-old brains, were performed using Tubingen-strain zebrafish maintained in a recirculated water system. This work with zebrafish was conducted under the auspices of the Animal Ethics Committee of the University of Adelaide (permit no. 31945) and Institutional Biosafety Committee (IBC Dealing ID 122210). The digital PCRs for psen1 transcript expression in 6-month-old brain experiments were performed using samples from Tubingen and AB-strain zebrafish maintained in a recirculated water system. This work with zebrafish was conducted under the auspices of the Macquarie University Animal Ethics Committee (permit no. 2015/034).
psen1 mutations
The isolation of the psen1K97fs and psen1Q96_K97del mutations has previously been described (31,30). Mutations were only analysed in the heterozygous state in this study.
Genomic DNA extraction and genotyping PCR of zebrafish tissue
DNA was extracted from adult zebrafish tail clips and genotyped via PCR as described in (31). Primers used for genotyping PCR were synthesized by Sigma-Aldrich Corp. St. Louis, Missouri, USA. Oligonucleotide sequences are given in Table 4.
Table 4.
Primer sequences for genotyping, sequencing and dqPCR. WT denotes wild-type allele-specific PCR. The WT primer target site for psen1 or PSEN1 is indicated in parentheses
| Gene symbol | Accession number | Target allele binding site | Sense primer (5′ → 3′) | Anti-sense primer (5′ → 3′) |
|---|---|---|---|---|
| Genotyping (genomic DNA) | ||||
| psen1 | ENSDARG00000004870 | WT (K97 site) | TCTGTCAGCTTCTACACACAGAAGG | CCATCCCTAAACTGCTCCTACTC |
| psen1 | ENSDARG00000004870 | GAdel (K97fs) | AATCTGTCAGCTTCTACACACAAGG | CCATCCCTAAACTGCTCCTACTC |
| psen1 | ENSDARG00000004870 | CAGAAGdel (Q96_K97del) | TGTCAGCTTCTACACAGACGGA | CCATCCCTAAACTGCTCCTACTC |
| psen1 | ENSDARG00000004870 | WT (exon 4-intron) | GGCACACAAGCAGCACCG | TCCTTTCCTGTCATTCAGACCTGCGA |
| psen1 | ENSDARG00000004870 | WT-sequencing | AGCCGTAATGAGGTGGAGC | N/A |
| dqPCR (cDNA) | ||||
| psen1 | NM_131024 | WT (K97 site) | CTACACACAGAAGGACGGACAGC | GCCAGGCTTGAATCACCTTGTA |
| psen1 | NM_131024 | GAdel (K97fs) | TCTGTCAGCTTCTACACACAAGGA | GCCAGGCTTGAATCACCTTGTA |
| psen1 | NM_131024 | CAGAAGdel (Q96_K97del) | TGTCAGCTTCTACACAGACGGA | GCCAGGCTTGAATCACCTTGTA |
| PSEN1 | NM_000021.3 | WT (L271 site) | CATTACTGTTGCACTCCTGATC | CTCCTGAGCTGTTTCAACCAG |
| PSEN1 | NM_000021.3 | L271V mutation | CATTACTGTTGCACTCCTGATC | CTCCTGAGCTGTTTCAACCAC |
| PSEN1 | NM_000021.3 | WT (L219 site) | CATTACTGTTGCACTCCTGATC | ATGCCTGCTGGAGTCGAA |
| PSEN1 | NM_000021.3 | L219P mutation | CATTACTGTTGCACTCCTGATC | GCCTGCTGGAGTCGAGG |
| PSEN1 | NM_000021.3 | WT (G206 site) | GGTCATCCATGCCTGGC | GGAAATCATTCCCACCACAC |
| PSEN1 | NM_000021.3 | G206V mutation | GGTCATCCATGCCTGGC | GGAAATCATTCCCACCACAA |
| PSEN2 | NM_012486.2 | WT | CATGATCGTGGTGGTAGCC | GGATGAACTTGTAGCAGCGG |
| CYC1 | NM_001916 | WT | AGCCTACAAGAAAGTTTGCCTAT | TCTTCTTCCGGTAGTGGATCTTGGC |
| RPL13 | NM_00977 | WT | CCTGGAGGAGAAGAGGAAAGAGA | TTGAGGACCTCTGTGTATTTGTCAA |
| cd44a | XM_001922456 | WT | CCCATCAGATTCATCACCAAACT | AGAATGAACTGTCTCTGGCTGC |
| mmp2 | NM_198067 | WT | CCTGAGACAGCAATGTCAACATCA | CATCATTGCGCCCTGATGTG |
| igfbp3 | NM_205751 | WT | AGTGCAGTCCATCCATCCAAAGGC | GTCTCCATGTTATAGCAGTGGACCT |
| pdk1 | XM_678484 | WT | ACAACCTGAATATAGTCTTAGC | GTGTGGAGTGTGATGATG |
Hypoxia treatment of adult zebrafish
Male or female adult zebrafish at the desired age and genotype were treated in low oxygen levels by placing zebrafish in oxygen-depleted water for 3 h (oxygen concentration of 6.6 ± 0.2 mg/L in normoxia and 0.6 ± 0.2 mg/L in hypoxia. Brains were subsequently used for digital PCR or western blotting analysis.
Whole brain removal from adult zebrafish
Adult fish were euthanized by sudden immersion in an ice water slurry for at least 30 s before immediate decapitation. The entire brain was then removed from the cranium for immediate RNA or protein extraction. All fish brains were sampled during late morning/noon to minimize effects of circadian rhythms. For the dqPCR psen1 allele-specific experiments on 6-months-old zebrafish, whole heads were stored in RNAlater (Ambion, Inc, Foster City, California, USA, AM1312) prior to brain removal and total RNA extraction.
RNA extraction and cDNA synthesis of total adult zebrafish brain
Total RNA was extracted from whole zebrafish brain (~10 mg) using the (QIAGEN, Venlo, Netherlands, 74104) QIAGEN RNeasy Mini Kit according to the manufacture’s protocol as described in (14,60). The RNA for dqPCR HRG experiments was DNase treated using RQ1 DNase from Promega (Madison, Wisconsin, USA) according to the manufacturer’s instructions. The RNA for dqPCR psen1 allele-specific experiments was DNase treated using the DNA-free™ Kit from Ambion, Life Technologies according to the manufacturer’s instructions. RNA was quantified using a NanoDrop spectrophotometer. cDNA was synthesized using random hexamers and the Superscript III First Strand Synthesis System (Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions.
RNA extraction and cDNA synthesis from human brain tissue
Human brain tissues were obtained from the Sydney Brain Bank at Neuroscience Research Australia and the NSW Brain Tissue Resource Centre at the University of Sydney. The brains were collected under institutional ethics approvals. Whole brains were sliced into blocks and fresh-frozen and stored at −80°C. Tissue samples from three cases with mutant PSEN1 and three age- and gender-matched controls without significant neuropathology (see Table 3 for details) were processed for RNA extraction using TRIzol reagent (Invitrogen Camarillo, California, USA) following the manufacturer’s protocol. All procedures were carried out using RNase-free reagents and consumables. Five micrograms of RNA were reverse transcribed into cDNA using Moloney-murine leukaemia virus reverse transcriptase and random primers (Promega) in a 20 μl reaction volume. RNA integrity was assessed with high resolution capillary electrophoresis (Agilent Technologies, Santa Clara, California, USA) and only RNA with RNA integrity number value greater than 6.0 was used.
Table 3.
Human PSEN1 mutations analysed for allele-specific dqPCR including age-matched control details. Post-mortem delay (PMD)
| PSEN1 mutation | Codon change | Gender | Age at death (years) | Disease duration (years) | PMD (hours) | Project ID |
|---|---|---|---|---|---|---|
| L271V | CTG to GTG | Female | 51 | 5 | 5 | LA1 |
| L219P | CTT to CCT | Female | 61 | 7 | 13 | LA2 |
| G206V | GGT to GTT | Female | 32 | 3 | 22 | LA3 |
| Control (L271V) | N/A | Female | 51 | N/A | 41 | LC2 |
| Control (L219P) | N/A | Female | 60 | N/A | 41 | LC1 |
| Control (G206V) | N/A | Female | 29 | N/A | 40 | LC3 |
3D Quant Studio Digital PCR
Digital PCR was performed on a QuantStudio™ 3D Digital PCR System (Life Technologies, Carlsbad, California, USA). Reaction mixes contained 1X QuantStudio™3D digital PCR Master Mix, Sybr® dye, 200 nm of specific primers and 12.5–500 ng cDNA (500 ng for PSEN1 and PSEN2, 100 ng for CYC1 and RPL13, 50 ng for cd44a, igfbp3, psen1 25 ng for pdk1 and 12.5 ng for mmp2). The reaction mixture (14.5 μl) was loaded onto a QuantStudio™3D digital PCR 20 K chip using an automatic chip loader according to the manufacturer’s instructions. Loaded chips underwent thermo-cycling on the Gene Amp 9700 thermo-cycling system under the following conditions: 96°C for 10 min, 39 cycles of 60°C (59°C for CYC1 and PSEN1G206Vsite) for 2 min and 98°C for 30 s, followed by a final extension step at 60°C (or 59°C see above) for 2 min. The chips were imaged on a QuantStudio™ 3D instrument, which assesses raw data and calculates the estimated concentration of the nucleic acid sequence targeted by the Sybr® dye by Poisson distribution (87). Primers used were synthesized by Sigma-Aldrich and are listed in Table 2.
Protein extraction of total adult zebrafish brain
Each brain was homogenized in water supplemented with Sample Reducing Agent (10×, contains 500 mm dithiothreitol) (Thermo Fisher Scientific) and Complete Protease Inhibitors (Roche Life Sciences, Basel, Switzerland). LDS buffer (Thermo Fisher Scientific) was then added and the sample was briefly homogenized and placed at 90°C for 20 min. Each sample was divided into several aliquots. To generate a protein standard to allow quantitative comparison between signals on separate western blots, eight male non-mutant adult zebrafish at 6 months of age were selected and placed under hypoxia as described in (14). Protein was extracted from each brain as above. After extraction all homogenates were combined, thoroughly mixed and divided into several aliquots, with one aliquot being sufficient for one Nu-PAGE gel (i.e. 3 × 10 μl for three lanes). All samples and standards were stored at −80°C until required.
Protein immunoblotting
Samples and standards were prepared by sonication for 10 min followed by incubation at 90°C for 5 min. PrecisionPlusProteinDualXtra ladder (Bio-Rad, Hercules, California, USA) (7 μl), standards (3 × 10 μl) and samples (6 × ~18 μl) were loaded on a 4–12% Bis-Tris Nu-PAGE (Life Technologies) gel for electrophoresis. The protein samples and standards were subsequently transferred to a PVDF membrane using the Mini Blot Module transfer system according to the manufacturer’s protocol (Thermo Fisher Scientific). To detect the Hif1ab protein, the membrane was initially blocked in 3%w/v skim milk powder followed by incubation in a 1/3000 dilution of the Hif1ab antibody (Gene Tex, Irvine, California, USA, cat no. GTX131826). The membrane was washed and incubated in a 1/2500 dilution of the rabbit-HRP secondary antibody (Sigma-Aldrich). After washing, Hif1ab protein was detected on the membrane using ECL detection reagents (Thermo Fisher Scientific) and visualized using the Chemi Doc Imaging System (Bio-Rad). The Hif1ab protein band can be observed at ~ 100 kDa. Using Image Lab software (Bio-Rad), a densitometry analysis was performed for the Hif1ab protein band for each sample and standard. An average value was obtained for the standards for each membrane. Each sample value was then normalized to the average standard value. Each protein sample was quantified using the EZQ protein quantification kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. The standard normalized value for each sample was then expressed as Hif1ab per total protein loaded. Each membrane displayed 3 normoxia and 3 hypoxia samples from the same age (6 or 24 months) and the same genotype (+/+, psen1Q96_K97del/+ or psen1K97fs/+) together with the protein standard in 3 separate lanes.
L-Lactate content analysis of zebrafish brain
L-Lactate content was analysed using the Lactate Colorimetric Kit II (BioVision Milpitas, California, USA). Brains were removed from zebrafish adults in cold 1× PBS, then weighed and homogenized in the Lactate Assay Buffer provided in the kit. Each sample was then filtered through a 10 kDa MW spin filter (Sartorius Stedim Biotech, Göttingen, Germany) to remove all proteins. The lactate content of the eluate from each zebrafish brain was determined using the kit according to the manufacturer’s protocol and the original brain weight was used to calculate the nmol of lactate per mg of brain tissue.
Conflict of Interest statement. None declared.
Funding
Australia’s National Health and Medical Research Council (1126422); Family of Lindsay Carthew (M.N.); The University of New South Wales; Neuroscience Research Australia; National Institute of Alcohol Abuse and Alcoholism (R24AA012725); National Health and Medical Research Council of Australia (1079679 to G.M.H.); National Health and Medical Research Council of Australia (1037746 and #1095127).
Supplementary Material
References
- 1. Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E. and Bateman, R.J. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 330, 1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P.et al. (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol., 12, 357–367. [DOI] [PubMed] [Google Scholar]
- 3. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M.et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med., 367, 795–804. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Iturria-Medina, Y., Sotero, R.C., Toussaint, P.J., Mateos-Perez, J.M., Evans, A.C. and Alzheimer's Disease Neuroimaging, I. (2016) Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat. Commun., 7, 11934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Karran, E. and De Strooper, B. (2016) The amyloid cascade hypothesis: are we poised for success or failure? J. Neurochem., 139, 237–252. [DOI] [PubMed] [Google Scholar]
- 6. Doig, A.J., Del Castillo-Frias, M.P., Berthoumieu, O., Tarus, B., Nasica-Labouze, J., Sterpone, F., Nguyen, P.H., Hooper, N.M., Faller, P. and Derreumaux, P. (2017) Why is research on amyloid-beta failing to give new drugs for Alzheimer's disease? ACS Chem. Nerosci., 8, 1435–1437. [DOI] [PubMed] [Google Scholar]
- 7. de Bruijn, R.F. and Ikram, M.A. (2014) Cardiovascular risk factors and future risk of Alzheimer's disease. BMC Med., 12, 130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. O'Brien, J.T. and Markus, H.S. (2014) Vascular risk factors and Alzheimer's disease. BMC Med., 12, 218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Reitz, C. and Mayeux, R. (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol., 88, 640–651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Panza, G.A., Taylor, B.A., MacDonald, H.V., Johnson, B.T., Zaleski, A.L., Livingston, J., Thompson, P.D. and Pescatello, L.S. (2018) Can exercise improve cognitive symptoms of Alzheimer's disease? A meta-analysis. J. Am. Geriatr. Soc., 66, 487–495. [DOI] [PubMed] [Google Scholar]
- 11. Kirk-Sanchez, N.J. and McGough, E.L. (2014) Physical exercise and cognitive performance in the elderly: current perspectives. Clin. Interv. Aging, 9, 51–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Daulatzai, M.A. (2017) Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. J. Neurosci. Res., 95, 943–972. [DOI] [PubMed] [Google Scholar]
- 13. Crawford, J.G. (1996) Alzheimer's disease risk factors as related to cerebral blood flow. Med. Hypotheses, 46, 367–377. [DOI] [PubMed] [Google Scholar]
- 14. Moussavi Nik, S.H., Wilson, L., Newman, M., Croft, K., Mori, T.A., Musgrave, I. and Lardelli, M. (2012) The BACE1-PSEN-AbetaPP regulatory axis has an ancient role in response to low oxygen/oxidative stress. J. Alzheimers Dis., 28, 515–530. [DOI] [PubMed] [Google Scholar]
- 15. Lukiw, W.J., Gordon, W.C., Rogaev, E.I., Thompson, H. and Bazan, N.G. (2001) Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis. Neuroreport, 12, 53–57. [DOI] [PubMed] [Google Scholar]
- 16. Tamagno, E., Guglielmotto, M., Aragno, M., Borghi, R., Autelli, R., Giliberto, L., Muraca, G., Danni, O., Zhu, X., Smith, M.A.et al. (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J. Neurochem., 104, 683–695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Wang, Z., Wu, D. and Vinters, H.V. (2002) Hypoxia and reoxygenation of brain microvascular smooth muscle cells in vitro: cellular responses and expression of cerebral amyloid angiopathy-associated proteins. APMIS, 110, 423–434. [DOI] [PubMed] [Google Scholar]
- 18. Oresic, M., Hyotylainen, T., Herukka, S.K., Sysi-Aho, M., Mattila, I., Seppanan-Laakso, T., Julkunen, V., Gopalacharyulu, P.V., Hallikainen, M., Koikkalainen, J.et al. (2011) Metabolome in progression to Alzheimer's disease. Transl. Psychiatry, 1, e57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I. and Gong, C.X. (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett., 582, 359–364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Guerreiro, R. and Hardy, J. (2014) Genetics of Alzheimer's disease. Neurotherapeutics, 11, 732–737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Jayadev, S., Leverenz, J.B., Steinbart, E., Stahl, J., Klunk, W., Yu, C.E. and Bird, T.D. (2010) Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain, 133, 1143–1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Zhu, X.C., Tan, L., Wang, H.F., Jiang, T., Cao, L., Wang, C., Wang, J., Tan, C.C., Meng, X.F. and Yu, J.T. (2015) Rate of early onset Alzheimer's disease: a systematic review and meta-analysis. Ann. Transl. Med., 3, 38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Masters, C.L., Bateman, R.J., Blennow, K., Rowe, C.C., Sperling, R.A. and Cummings, J.L. (2015) Alzheimer's disease. Nat. Rev. Dis. Primers., 1, 1–8. [DOI] [PubMed] [Google Scholar]
- 24. Pottier, C., Hannequin, D., Coutant, S., Rovelet-Lecrux, A., Wallon, D., Rousseau, S., Legallic, S., Paquet, C., Bombois, S., Pariente, J.et al. (2012) High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol. Psychiatry, 17, 875–879. [DOI] [PubMed] [Google Scholar]
- 25. Jayne, T., Newman, M., Verdile, G., Sutherland, G., Munch, G., Musgrave, I., Moussavi Nik, S.H. and Lardelli, M. (2016) Evidence for and against a pathogenic role of reduced gamma-secretase activity in familial Alzheimer's disease. J. Alzheimers Dis., 52, 781–799. [DOI] [PubMed] [Google Scholar]
- 26. Lumsden, A.L., Rogers, J.T., Majd, S., Newman, M., Sutherland, G.T., Verdile, G. and Lardelli, M. (2018) Dysregulation of neuronal iron homeostasis as an alternative unifying effect of mutations causing familial Alzheimer's disease. Front. Neurosci., 12, 533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Quiroz, Y.T., Schultz, A.P., Chen, K., Protas, H.D., Brickhouse, M., Fleisher, A.S., Langbaum, J.B., Thiyyagura, P., Fagan, A.M., Shah, A.R.et al. (2015) Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol., 72, 912–919. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Reiman, E.M., Quiroz, Y.T., Fleisher, A.S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A.M., Shah, A.R., Alvarez, S., Arbelaez, A.et al. (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol., 11, 1048–1056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Gordon, B.A., Blazey, T.M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C.et al. (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol., 17, 241–250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Newman, M., Hin, N., Pederson, S. and Lardelli, M. (2019) Brain transcriptome analysis of a familial Alzheimer’s disease-like mutation in the zebrafish presenilin 1 gene implies effects on energy production. Mol Brain, 12, 43. https://doi.org/10.1186/s13041-019-0467-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Hin, N., Newman, M., Kaslin, J., Douek, A.M., Lumsden, A., Nik, S.H.M., Dong, Y., Zhou, X.F., Manucat-Tan, N.B., Ludington, A.et al. (2020) Accelerated brain aging towards transcriptional inversion in a zebrafish model of the K115fs mutation of human PSEN2. PLoS One, 15, e0227258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Braggin, J.E., Bucks, S.A., Course, M.M., Smith, C.L., Sopher, B., Osnis, L., Shuey, K.D., Domoto-Reilly, K., Caso, C., Kinoshita, C.et al. (2019) Alternative splicing in a presenilin 2 variant associated with Alzheimer disease. Ann. Clin. Transl. Neurol., 6, 762–777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. De Strooper, B. (2007) Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep., 8, 141–146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Wang, B., Yang, W., Wen, W., Sun, J., Su, B., Liu, B., Ma, D., Lv, D., Wen, Y., Qu, T.et al. (2010) Gamma-secretase gene mutations in familial acne inversa. Science, 330, 1065. [DOI] [PubMed] [Google Scholar]
- 35. Area-Gomez, E., de Groof, A.J., Boldogh, I., Bird, T.D., Gibson, G.E., Koehler, C.M., Yu, W.H., Duff, K.E., Yaffe, M.P., Pon, L.A.et al. (2009) Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am. J. Pathol., 175, 1810–1816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Newman, M., Hin, N., Pederson, S. and Lardelli, M. (2019) Brain transcriptome analysis of a familial Alzheimer's disease-like mutation in the zebrafish presenilin 1 gene implies effects on energy production. Mol. Brain, 12, 43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. De Gasperi, R., Sosa, M.A., Dracheva, S. and Elder, G.A. (2010) Presenilin-1 regulates induction of hypoxia inducible factor-1alpha: altered activation by a mutation associated with familial Alzheimer's disease. Mol. Neurodegener., 5, 38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Villa, J.C., Chiu, D., Brandes, A.H., Escorcia, F.E., Villa, C.H., Maguire, W.F., Hu, C.J., de Stanchina, E., Simon, M.C., Sisodia, S.S.et al. (2014) Nontranscriptional role of Hif-1alpha in activation of gamma-secretase and notch signaling in breast cancer. Cell Rep., 8, 1077–1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Harris, A.L. (2002) Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38–47. [DOI] [PubMed] [Google Scholar]
- 40. Kim, J.W., Tchernyshyov, I., Semenza, G.L. and Dang, C.V. (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 3, 177–185. [DOI] [PubMed] [Google Scholar]
- 41. Paolicchi, E., Gemignani, F., Krstic-Demonacos, M., Dedhar, S., Mutti, L. and Landi, S. (2016) Targeting hypoxic response for cancer therapy. Oncotarget, 7, 13464–13478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Kuang, X., Liu, C., Fang, J., Ma, W., Zhang, J. and Cui, S. (2016) The tumor suppressor gene lkb1 is essential for glucose homeostasis during zebrafish early development. FEBS Lett., 590, 2076–2085. [DOI] [PubMed] [Google Scholar]
- 43. Caceda, R., Gamboa, J.L., Boero, J.A., Monge, C.C. and Arregui, A. (2001) Energetic metabolism in mouse cerebral cortex during chronic hypoxia. Neurosci. Lett., 301, 171–174. [DOI] [PubMed] [Google Scholar]
- 44. Gerhard, G.S., Kauffman, E.J., Wang, X., Stewart, R., Moore, J.L., Kasales, C.J., Demidenko, E. and Cheng, K.C. (2002) Life spans and senescent phenotypes in two strains of Zebrafish (Danio rerio). Exp. Gerontol., 37, 1055–1068. [DOI] [PubMed] [Google Scholar]
- 45. He, F. and Jacobson, A. (2015) Nonsense-mediated mRNA decay: degradation of defective transcripts is only part of the story. Annu. Rev. Genet., 49, 339–366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. El-Brolosy, M.A., Kontarakis, Z., Rossi, A., Kuenne, C., Gunther, S., Fukuda, N., Kikhi, K., Boezio, G.L.M., Takacs, C.M., Lai, S.L.et al. (2019) Genetic compensation triggered by mutant mRNA degradation. Nature, 568, 193–197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Ndubuizu, O.I., Chavez, J.C. and LaManna, J.C. (2009) Increased prolyl 4-hydroxylase expression and differential regulation of hypoxia-inducible factors in the aged rat brain. Am. J. Physiol. Regul. Integr. Comp. Physiol., 297, R158–R165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Ndubuizu, O.I., Tsipis, C.P., Li, A. and LaManna, J.C. (2010) Hypoxia-inducible factor-1 (HIF-1)-independent microvascular angiogenesis in the aged rat brain. Brain Res., 1366, 101–109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Blair, J.E. and Hedges, S.B. (2005) Molecular phylogeny and divergence times of deuterostome animals. Mol. Biol. Evol., 22, 2275–2284. [DOI] [PubMed] [Google Scholar]
- 50. Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J. and Yankner, B.A. (2004) Gene regulation and DNA damage in the ageing human brain. Nature, 429, 883–891. [DOI] [PubMed] [Google Scholar]
- 51. Patel, A., Malinovska, L., Saha, S., Wang, J., Alberti, S., Krishnan, Y. and Hyman, A.A. (2017) ATP as a biological hydrotrope. Science, 356, 753–756. [DOI] [PubMed] [Google Scholar]
- 52. Kaufmann, T., van der Meer, D., Doan, N.T., Schwarz, E., Lund, M.J., Agartz, I., Alnaes, D., Barch, D.M., Baur-Streubel, R., Bertolino, A.et al. (2019) Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nat. Neurosci., 22, 1617–1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Eberling, J.L., Jagust, W.J., Reed, B.R. and Baker, M.G. (1992) Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol. Aging, 13, 483–491. [DOI] [PubMed] [Google Scholar]
- 54. Johnson, K.A., Jones, K., Holman, B.L., Becker, J.A., Spiers, P.A., Satlin, A. and Albert, M.S. (1998) Preclinical prediction of Alzheimer's disease using SPECT. Neurology, 50, 1563–1571. [DOI] [PubMed] [Google Scholar]
- 55. Raz, L., Bhaskar, K., Weaver, J., Marini, S., Zhang, Q., Thompson, J.F., Espinoza, C., Iqbal, S., Maphis, N.M., Weston, L.et al. (2019) Hypoxia promotes tau hyperphosphorylation with associated neuropathology in vascular dysfunction. Neurobiol. Dis., 126, 124–136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Mesulam, M.M. (1999) Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron, 24, 521–529. [DOI] [PubMed] [Google Scholar]
- 57. Berchtold, N.C., Sabbagh, M.N., Beach, T.G., Kim, R.C., Cribbs, D.H. and Cotman, C.W. (2014) Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. Neurobiol. Aging, 35, 1961–1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Head, E., Lott, I.T., Patterson, D., Doran, E. and Haier, R.J. (2007) Possible compensatory events in adult down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J. Alzheimers Dis., 11, 61–76. [DOI] [PubMed] [Google Scholar]
- 59. Arnemann, K.L., Stober, F., Narayan, S., Rabinovici, G.D. and Jagust, W.J. (2018) Metabolic brain networks in aging and preclinical Alzheimer's disease. Neuroimage Clin., 17, 987–999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Moussavi Nik, S.H., Newman, M., Wilson, L., Ebrahimie, E., Wells, S., Musgrave, I., Verdile, G., Martins, R.N. and Lardelli, M. (2015) Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of gamma-secretase activity. Hum. Mol. Genet., 24, 3662–378. [DOI] [PubMed] [Google Scholar]
- 61. Sato, N., Hori, O., Yamaguchi, A., Lambert, J.C., Chartier-Harlin, M.C., Robinson, P.A., Delacourte, A., Schmidt, A.M., Furuyama, T., Imaizumi, K.et al. (1999) A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J. Neurochem., 72, 2498–2505. [DOI] [PubMed] [Google Scholar]
- 62. Katayama, T., Imaizumi, K., Manabe, T., Hitomi, J., Kudo, T. and Tohyama, M. (2004) Induction of neuronal death by ER stress in Alzheimer's disease. J. Chem. Neuroanat., 28, 67–78. [DOI] [PubMed] [Google Scholar]
- 63. Heilig, E.A., Gutti, U., Tai, T., Shen, J. and Kelleher, R.J., 3rd. (2013) Trans-dominant negative effects of pathogenic PSEN1 mutations on gamma-secretase activity and Abeta production. J. Neurosci., 33, 11606–11617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Pera, M., Larrea, D., Guardia-Laguarta, C., Montesinos, J., Velasco, K.R., Agrawal, R.R., Xu, Y., Chan, R.B., Di Paolo, G., Mehler, M.F.et al. (2017) Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J., 36, 3356–3371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Takami, K., Terai, K., Matsuo, A., Walker, D.G. and McGeer, P.L. (1997) Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer's disease brains. Brain Res., 748, 122–130. [DOI] [PubMed] [Google Scholar]
- 66. Isoe-Wada, K., Urakami, K., Wakutani, Y., Adachi, Y., Arai, H., Sasaki, H. and Nakashima, K. (1999) Alteration in brain presenilin-1 mRNA expression in sporadic Alzheimer's disease. Eur. J. Neurol., 6, 163–167. [DOI] [PubMed] [Google Scholar]
- 67. Ikeda, K., Urakami, K., Arai, H., Wada, K., Wakutani, Y., Ji, Y., Adachi, Y., Okada, A., Kowa, H., Sasaki, H.et al. (2000) The expression of presenilin 1 mRNA in skin fibroblasts and brains from sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 11, 245–250. [DOI] [PubMed] [Google Scholar]
- 68. Borghi, R., Piccini, A., Barini, E., Cirmena, G., Guglielmotto, M., Tamagno, E., Fornaro, M., Perry, G., Smith, M.A., Garuti, A.et al. (2010) Upregulation of presenilin 1 in brains of sporadic, late-onset Alzheimer's disease. J. Alzheimers Dis., 22, 771–775. [DOI] [PubMed] [Google Scholar]
- 69. Farnsworth, B., Peuckert, C., Zimmermann, B., Jazin, E., Kettunen, P. and Emilsson, L.S. (2016) Gene expression of quaking in sporadic Alzheimer's disease patients is both upregulated and related to expression levels of genes involved in amyloid plaque and neurofibrillary tangle formation. J. Alzheimers Dis., 53, 209–219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Johnston, J.A., Froelich, S., Lannfelt, L. and Cowburn, R.F. (1996) Quantification of presenilin-1 mRNA in Alzheimer's disease brains. FEBS Lett., 394, 279–284. [DOI] [PubMed] [Google Scholar]
- 71. Delabio, R., Rasmussen, L., Mizumoto, I., Viani, G.A., Chen, E., Villares, J., Costa, I.B., Turecki, G., Linde, S.A., Smith, M.C.et al. (2014) PSEN1 and PSEN2 gene expression in Alzheimer's disease brain: a new approach. J. Alzheimers Dis., 42, 757–760. [DOI] [PubMed] [Google Scholar]
- 72. Qiu, C. and Fratiglioni, L. (2018) Aging without dementia is achievable: current evidence from epidemiological research. J. Alzheimers Dis., 62, 933–942. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Boeve, B., McCormick, J., Smith, G., Ferman, T., Rummans, T., Carpenter, T., Ivnik, R., Kokmen, E., Tangalos, E., Edland, S.et al. (2003) Mild cognitive impairment in the oldest old. Neurology, 60, 477–480. [DOI] [PubMed] [Google Scholar]
- 74. Andersen-Ranberg, K., Vasegaard, L. and Jeune, B. (2001) Dementia is not inevitable: a population-based study of Danish centenarians. J. Gerontol. B Psychol. Sci. Soc. Sci., 56, P152–P159. [DOI] [PubMed] [Google Scholar]
- 75. Hin, N., Newman, M., Pederson, S. and Lardelli, M. (2020) Iron responsive element (IRE)-mediated responses to iron dyshomeostasis in Alzheimer’s disease. bioRxiv, in press, 2020.2005.2001.071498. [DOI] [PubMed] [Google Scholar]
- 76. Skaggs, K., Goldman, D. and Parent, J.M. (2014) Excitotoxic brain injury in adult zebrafish stimulates neurogenesis and long-distance neuronal integration. Glia, 62, 2061–2079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Solchenberger, B., Russell, C., Kremmer, E., Haass, C. and Schmid, B. (2015) Granulin knock out zebrafish lack frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis pathology. PLoS One, 10, e0118956. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Le Moan, N., Houslay, D.M., Christian, F., Houslay, M.D. and Akassoglou, K. (2011) Oxygen-dependent cleavage of the p75 neurotrophin receptor triggers stabilization of HIF-1alpha. Mol. Cell, 44, 476–490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Peyssonnaux, C., Zinkernagel, A.S., Schuepbach, R.A., Rankin, E., Vaulont, S., Haase, V.H., Nizet, V. and Johnson, R.S. (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest., 117, 1926–1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Lane, D.J., Merlot, A.M., Huang, M.L., Bae, D.H., Jansson, P.J., Sahni, S., Kalinowski, D.S. and Richardson, D.R. (2015) Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease. Biochim. Biophys. Acta, 1853, 1130–1144. [DOI] [PubMed] [Google Scholar]
- 81. Yambire, K.F., Rostosky, C., Watanabe, T., Pacheu-Grau, D., Torres-Odio, S., Sanchez-Guerrero, A., Senderovich, O., Meyron-Holtz, E.G., Milosevic, I., Frahm, J.et al. (2019) Impaired lysosomal acidification triggers iron deficiency and inflammation in vivo. Elife, 8, e51031. doi: 10.7554/eLife.51031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82. Muller, S., Preische, O., Sohrabi, H.R., Graber, S., Jucker, M., Ringman, J.M., Martins, R.N., McDade, E., Schofield, P.R., Ghetti, B.et al. (2018) Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimers Dement., 14, 1427–1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Santos-Lozano, A., Pareja-Galeano, H., Sanchis-Gomar, F., Quindos-Rubial, M., Fiuza-Luces, C., Cristi-Montero, C., Emanuele, E., Garatachea, N. and Lucia, A. (2016) Physical activity and Alzheimer disease: a protective association. Mayo Clin. Proc., 91, 999–1020. [DOI] [PubMed] [Google Scholar]
- 84. Stephen, R., Hongisto, K., Solomon, A. and Lonnroos, E. (2017) Physical activity and Alzheimer's disease: a systematic review. J. Gerontol. A Biol. Sci. Med. Sci., 72, 733–739. [DOI] [PubMed] [Google Scholar]
- 85. Beydoun, M.A., Beydoun, H.A., Gamaldo, A.A., Teel, A., Zonderman, A.B. and Wang, Y. (2014) Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health, 14, 643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Frederiksen, K.S., Gjerum, L., Waldemar, G. and Hasselbalch, S.G. (2018) Effects of physical exercise on Alzheimer's disease biomarkers: a systematic review of intervention studies. J. Alzheimers Dis., 61, 359–372. [DOI] [PubMed] [Google Scholar]
- 87. Fazekas de St, G. (1982) The evaluation of limiting dilution assays. J. Immunol. Methods, 49, R11–R23. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
